Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: Results from a global antifungal surveillance program

Journal of Clinical Microbiology

Volumn 46, Issue 2, 2008, Pages 551-559

  Pfaller, M A ^a   Messer, S A ^a   Boyken, L ^a   Tendolkar, S ^a   Hollis, R J ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDA ZEYLANOIDES; FOOD AND DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YARROWIA LIPOLYTICA;

ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REGRESSION ANALYSIS; TRIAZOLES;

CANDIDA; ISSATCHENKIA ORIENTALIS;

EID: 38949182315     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01952-07     Document Type: Article

References (50)

1. Anstead, G. M., G. Corcoran, J. Lewis, D. Berg, and J. R. Graybill. 2005. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis. 40:1770-1776.
2. Borst, A., M. T. Raimer, D. W. Warnock, C. J. Marrison, and B. A. Arthington-Skaggs. 2005. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob. Agents Chemother. 49:783-787.
3. Chau, A. S., C. A. Mendrick, F. J. Sabatelli, D. Loebenberg, and P. M. Nichols. 2004. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob. Agents Chemother. 48:2124-2131.
4. Clinical and Laboratory Standards Institute. 2007. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline - third edition. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Cornely, O. A., J. Maertens, D. J. Winston, J. Perfect, A. J. Ullman, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y. T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
6. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzan, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
7. Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
8. Diekema, D. J., S. A. Messer, R. J. Hollis, L. B. Boyken, S. Tendolkar, J. Kroeger, and M. A. Pfaller. 2007. Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. J. Clin. Microbiol. 45:1974-1977.
9. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,062 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
10. Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C. Knapp, N. Holliday, and S. B. Killian. 2004. Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721.
11. Ferraro, M. J., and J. H. Jorgenson. 1995. Instrument-based antibacterial susceptibility testing, p. 1379-1384. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, DC.
12. Fukuoka, T., D. A. Johnston, C. A. Winslow, M. J. deGroot, C. Burt, C. A. Hitchcock, and S. G. Filler. 2003. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob. Agents Chemother. 47:1213-1219.
13. González, G. M., A. W. Fothergill, D. A. Sutton, M. G. Rinaldi, and D. Loebenberg. 2005. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. 43:281-284.
14. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgenson, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
15. Jones, R. N., M. A. Pfaller, and the SENTRY Antimicrobial Surveillance Program Participants Group (USA). 2001. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from the SENTRY Antimicrobial Surveillance Program (1997-99). Diagn. Microbiol. Infect. Dis. 39:237-243.
16. Jones, R. N., H. S. Sader, T. R. Fritsche, P. A. Hogan, and D. J. Sheehan. 2006. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. 44:2622-2625.
17. Li, X., N. Broun, A. S. Chau, J. L. Lopez-Ribot, M. T. Ruesga, G. Quindos, C. A. Mendrick, R. S. Hare, D. Loebenberg, B. DiDomenico, and P. M. McNicholas. 2004. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J. Antimicrob. Chemother. 53:74-80.
18. Lortholary, O., E. Dannaoui, D. Raoux, D. Hoinard, A. Datry, A. Paugam, J. L. Poirot, C. Lacroix, F. Dromer, and the YEASTS Group. 2007. In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 51:3378-3380.
19. Morace, G., G. Amato, F. Bistoni, G. Fadda, P. Marone, M. T. Montagna, S. Oliveri, L. Polonelli, R. Rigoli, I. Mancuso, S. La Face, L. Masucci, L. Romano, C. Napoli, D. Tatò, M. G. Buscema, C. M. C. Belli, M. M. Piccirillo, S. Conti, S. Covan, F. Fanti, C. Cavanna, F. D'Alò, and L. Pitzurra. 2002. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J. Clin. Microbiol. 40:2953-2958.
20. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
21. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility tests; approved standard, 8th ed., M2-A8. National Committee for Clinical Laboratory Standards, Wayne, PA.
22. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed., M7-A6. National Committee for Laboratory Standards, Wayne, PA.
23. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing; 13th informational supplement, M100-S13. National Committee for Clinical Laboratory Standards, Wayne, PA.
24. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
25. Pfaller, M. A., S. A. Messer, R. J. Hollis, and R. N. Jones. 2001. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45:2862-2864.
26. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro susceptibilities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
27. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, R. J. Hollis, and the SENTRY Participants Group. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:852-856.
28. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
29. Pfaller, M. A., A. Espinel-Ingroff, and R. N. Jones. 2004. Clinical evaluation of the Sensititre YeastOne Colorimetric Antifungal Plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J. Clin. Microbiol. 42:4577-4580.
30. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42:3137-3141.
31. Pfaller, M. A., and D. J. Diekema. 2004. 12 years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of Candida bloodstream isolates. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
32. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
33. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species testing against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
34. Pfaller, M. A., and R. N. Jones for the Microbiology Resource Committee of the College of American Pathologists. 2006. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists (CAP) Microbiology Surveys Program (2001-2003). Arch. Pathol. Lab. Med. 130:767-778.
35. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2007. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J. Clin. Microbiol. 45:70-75.
36. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
37. Pfaller, M. A., and D. J. Diekema. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1:74-92.
38. Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. 2007. Multicenter comparison of VITEK 2 Yeast Susceptibility Test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45:796-802.
39. Raad, I. I., R. Y. Hachem, R. Herbrecht, J. R. Graybill, R. Hare, G. Corcoran, and D. P. Kontoyiannis. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1389-1403.
40. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
41. Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
42. Sanglard, D., F. Ischer, D. Calabrese, P. A. Majcherczyk, and J. Bille. 1999. The ATP binding cassette transplant gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43:2753-2765.
43. Sanguinetti, M., B. Posteraro, B. Fieri, S. Ranno, R. Torelli, and G. Fadda. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679.
44. Sims, C. R., V. L. Paetznick, J. R. Rodriguez, J. R. Rodriguez, E. Chen, and L. Ostrosky-Zeichner. 2006. Correlation between microdilution, Etest, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J. Clin. Microbiol. 44:2105-2108.
45. Skiest, D. J., J. A. Vazquez, G. M. Anstead, J. R. Graybill, J. Reynes, D. Ward, R. Hare, N. Boparai, and R. Isaacs. 2007. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. 44:607-614.
46. Ullmann, A. J., O. A. Cornely, A. Burchardt, R. Hachem, D. P. Kontoyiannis, K. Topelt, R. Courtney, D. Wexler, G. Krishna, M. Martinho, G. Corcoran, and I. Raad. 2006. Pharmacokinetics safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or with refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666.
47. Ullmann, A. J., J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Longston, S. R. Tarantolo, H. Greinix, W. M. deAzevedo, V. Reddy, N. Boparai, L. Pedicane, H. Patino, and S. Durrant. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
48. Vazquez, J. A., D. J. Skeist, L. Nieto, R. Northland, I. Sanne, J. Gogate, W. Greaves, and R. Isaacs. 2006. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42:1179-1186.
49. Walsh, T. J., I. Raad, T. F. Patterson, P. Chandrasekar, G. R. Donowitz, R. Graybill, R. E. Greene, R. Hachem, S. Hadley, R. Herbrecht, A. Langston, A. Louie, P. Ribaud, B. H. Segal, D. A. Stevens, J. A. van Burik, C. S. White, G. Corcoran, J. Gogate, G. Krishna, L. Pedicone, C. Hardalo, and J. R. Perfect. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
50. Xiao, L., V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. McNicholas. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574.